<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04506671</url>
  </required_header>
  <id_info>
    <org_study_id>CA_vs_PN</org_study_id>
    <nct_id>NCT04506671</nct_id>
  </id_info>
  <brief_title>Percutaneous Cryoablation Versus Partial Nephrectomy for T1b Renal Tumor</brief_title>
  <official_title>A Prospective, Non-randomized, in Parallel Groups Study Evaluating the Efficacy and Safety of Percutaneous Cryoablation and Partial Nephrectomy in Localized T1b Renal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I.M. Sechenov First Moscow State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I.M. Sechenov First Moscow State Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to assess the long-term oncological and functional outcomes of&#xD;
      cryoablation for T1b renal tumors, as well as such important parameters as the patient's&#xD;
      quality of life after treatment, and to compare the results with those after partial&#xD;
      nephrectomy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">June 22, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 22, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>5 years</time_frame>
    <description>Local recurrance will be evaluated with CT after 6 months, a year, then annually - up to 5 years after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastatic progression</measure>
    <time_frame>5 years</time_frame>
    <description>Presence of metastases will be evaluated with CT after 6 months, a year, then annually - up to 5 years after the treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30)</measure>
    <time_frame>5 years</time_frame>
    <description>Quality of life will be assessed using scales EORTC QLQ C-30, ranging from 1 to 100, where higher score indicating a better Quality of Life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>5 years</time_frame>
    <description>Renal function will be evaluated with eGFR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse events</measure>
    <time_frame>3 months</time_frame>
    <description>Rate of intra- and postoperative adverse events will be assessed according to Clavien-Dindo grade system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood loss</measure>
    <time_frame>12 months</time_frame>
    <description>Pre- and postoperative Hb level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>1 month</time_frame>
    <description>Number of days spent in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain score</measure>
    <time_frame>5 years</time_frame>
    <description>Pain score will be assessed using visual analogue scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Renal Tumor</condition>
  <arm_group>
    <arm_group_label>Cryoablation group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with T1b renal tumor and ECOQ&gt;20</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Partial nephrectomy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with T1b renal tumor</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Renal biopsy</intervention_name>
    <description>Renal biopsy will be performed prior to the cryoablation on the basis of the center and according to the current protocols</description>
    <arm_group_label>Cryoablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Cryoablation under CT guidance will be performed on the basis of the center and according to the current protocols</description>
    <arm_group_label>Cryoablation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Partial nephrectomy</intervention_name>
    <description>Partial nephrectomy will be performed on the basis of the center and according to the current protocols</description>
    <arm_group_label>Partial nephrectomy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        â€¢CT-confirmed renal mass &gt; 4 to 7 cm (T1b)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple renal tumors;&#xD;
&#xD;
          -  Recurrence of renal tumor;&#xD;
&#xD;
          -  Intolerance to iodine-containing contrast agents;&#xD;
&#xD;
          -  Pregnancy;&#xD;
&#xD;
          -  Patients with Bosniak 4 cysts&#xD;
&#xD;
          -  Presence of other oncological diseases;&#xD;
&#xD;
          -  Impossibility of organ-preserving treatment due to the proximity of the tumor to the&#xD;
             vessels or the calyx-pelvic system&#xD;
&#xD;
          -  Absence of malignant pathology based on prior biopsy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institute for Urology and Reproductive Health, Sechenov University.</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Enikeev, M.D., Ph.D</last_name>
      <phone>+7 9670897154</phone>
      <email>enikeev-dv@1msmu.ru</email>
    </contact>
    <contact_backup>
      <last_name>Mark Taratkin, MD</last_name>
      <phone>+7 9670897154</phone>
      <email>marktaratkin@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 6, 2020</study_first_submitted>
  <study_first_submitted_qc>August 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2020</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>I.M. Sechenov First Moscow State Medical University</investigator_affiliation>
    <investigator_full_name>Dmitry Enikeev, MD, PhD</investigator_full_name>
    <investigator_title>Deputy Director for Research</investigator_title>
  </responsible_party>
  <keyword>Cryoablation</keyword>
  <keyword>Renal cancer</keyword>
  <keyword>Partial nephrectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

